News | May 16, 2025
Piramal Pharma reports Q4 FY25 consolidated net profit of Rs. 153.50 Cr
The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
Standalone profit from operations for the quarter were Rs. 162 crores
Ideal for extreme dry skin and hyperkeratotic conditions such as psoriasis and ichthyosis, Ureaderm offers the next step in evidence-based, effective skin hydration
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
EBITDA before special items decreases to €4.08 billion (7.4%)
_256_384.jpg)
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
Haloperidol Decanoate Injection indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy
Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
The company has posted net profit of Rs. 77.60 crores for the Financial Year ended March 31, 2025
Subscribe To Our Newsletter & Stay Updated
